Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.
IPO Year: 2018
Exchange: NASDAQ
Website: adialpharma.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/13/2021 | $12.00 | Buy | Brookline Capital |
6/29/2021 | $5.00 | Buy | Litchfield Hills |
SC 13G - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13D/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
10-Q - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
424B3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
EFFECT - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
424B5 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
S-3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
10-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
D - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "Throughout 2023 we
Charlottesville, Va., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Tony Goodman as Chief Operating Officer. A highly accomplished pharmaceutical industry executive and member of Adial's Board of Directors since 2017, Mr. Goodman will oversee the Company's strategic growth initiatives, including clinical development and commercial planning for AD04, as well as business development initiatives focused on partnership opportunities in the area
Brookline Capital initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $12.00
Litchfield Hills initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $5.00
On Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced the publication of previously disclosed results from its Phase 3 ONWARD study in a peer-reviewed article in the European Journal of Internal Medicine entitled, "Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes." The publication findings showed a significant difference in the monthly percentage of heavy drinking days between the company's lead asset, AD04 (low-dose ondansetron), and the placebo group among heavy drinking patients and specific genotypic variants. Related: EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Al
Wednesday, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) announced that the first patient had been dosed in a pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinking patients. The study is expected to take six months to complete and is intended to produce data that will help the company optimize the study design elements needed for the upcoming Phase 3 clinical trial of AD04. Completion of this study will also satisfy a requirement of the FDA guidance for the upcoming Phase 3 clinical trial of AD04. Related: EXCLUSIVE: Alcohol Disorder-Focused Adial Pharmaceuticals Secures US Patent. “This relatively short and low-cost study is also a key element of our strategy to a
Gainers Sharps Technology (NASDAQ:STSS) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 9.75% to $2.25. The market value of their outstanding shares is at $3.2 million. Lucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 6.89% to $0.93. The market value of their outstanding shares is at $1.6 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by 6.4% to $1.33. The company's market cap stands at $5.6 million. Aclaris Therapeutics (NASDAQ:ACRS) shares rose 5.4% to $1.17. The market value of their outstanding shares is at $83.3 mi
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(2.19) per share which missed the analyst consensus estimate of $(0.35) by 525.71 percent. This is a 20.36 percent increase over losses of $(2.75) per share from the same period last year.
Gainers Processa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock rose 23.04% to $2.83. The company's market cap stands at $3.7 million. Compass Therapeutics (NASDAQ:CMPX) shares rose 21.62% to $1.8. The market value of their outstanding shares is at $247.6 million. Virax Biolabs Group (NASDAQ:VRAX) shares increased by 19.37% to $0.79. The company's market cap stands at $1.8 million. Nuwellis (NASDAQ:NUWE) shares increased by 13.84% to $0.29. The company's market cap stands at $1.9 million. Can Fite Biofarma (AMEX:CANF) stock moved upwards by 12
Gainers Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. The company's market cap stands at $10.5 million. NKGen Biotech (NASDAQ:NKGN) shares moved upwards by 32.0% to $1.46. The company's market cap stands at $33.2 million. The company's, Q4 earnings came out 4 days ago. T2 Biosystems (NASDAQ:TTOO) shares moved upwards by 18.91% to $3.52. The company's market cap stands at $30.9 million. CNS Pharma (NASDAQ:CNSP) shares increased by 18.26% to $0.24. The company's market cap stands at $2.5 million. Altamira Therapeutics (NASDAQ:CYTO) stock moved upwards by 17.39% to $1.66. The market value of their outstanding shares is at $3.7 million. D
On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc (NASDAQ:ADIL). This patent expands Adial’s intellectual property protection and covers the combination of the company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the company’s lead investigational new drug product AD04. Related: EXCLUSIVE: Adial Pharmaceuticals Announces New US Patent Covering Its Molecular Genetic Diagnosing For Alcohol, Drug Dependence. Cary Claiborne, CEO of Adial, commented,
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of previously disclosed results from its Phase 3 ONWARD study in a peer-reviewed article in the European Journal of Internal Medicine entitled, "Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes." The publication findings showed a significant difference in the monthly percentage of heavy drinking days between the Company's lead asset, AD04 (low-
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Today the MicroCap Rodeo - Spring into Summer will take place in-person on Thursday, June 6th, 2024 and host the executive management teams of 25 microcap companies.The conference will be held live at Convene NYC, with company presentations from beginning at 9:00 AM ET. They will also be webcast live on Thursday, June 6th. You may register to view the webcasts below, or register at the event website: https://www.microcaprodeo.com/signup1x1 Meetings are being held all-day Thursday, June 6th beginning at 9:00 AM ET for qualified investors.At 12 noon ET we will have special guest speaker: Alan Sheriff from Catalyst Corporation Advisory, "Bringing Large
Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va., June 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that the first patient has been dosed in a pharmacokinetics study of AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in hea
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City. Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m. Eastern Time on Thursday, June 6th. The presentation will be webcast live and available at https://www.webcaster4.com/Webcast/Page/3045/50687 as well as on the Company's investor relat
GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "We are making steady progress as it relates to AD04. We have initiated new activities related to our clinical development plan after incorporating favorable feedback received from the FDA last year. We anticipate conducting two parallel Phase 3 clinical trials
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office. This patent expands Adial's intellectual property protection and covers the combination of the Company's proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with th
GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD04 (low-dose ondansetron), the Company's lead investigational new drug product being developed for the treatment of Alcohol Use Disorder (AUD). The publication also reported the results of a new study analyzing the liver safety profile of AD04 compared with plac
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "Throughout 2023 we
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the Company originally issued in October 2023, having an exercise price of $2.82 per share and eighteen months term. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statemen
CHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,905,562 was issued on February 20, 2024 by the United States Patent and Trademark Office. The patent covers the Company's lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder (OUD). "We are proud to be awarded another important patent that broadens our Intellectual Property portfolio
Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authorities Adial in discussions with potential pharma partners Conference call to be held at 8:15 a.m. EST tomorrow CHARLOTTESVILLE, Va., March 06, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company") a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update on its regulatory strategy for AD04, the Company's lead compound for the treatment of Alcohol Use Disorder (A
CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will host a conference call and webcast on Tuesday, March 7, 2023, at 8:15 a.m. Eastern Time, to provide an update on its regulatory and partnering strategy for the United States and Europe. The company will also present and discuss the findings from its subgroup analysis of ONWARD data. A live audio webcast of the conference call and accompanying slide presentation may be accessed at https
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking AD04 demonstrated statistically significant difference in AUD severity, as compared to placebo, with an 84% decrease in the number of heavy drinking patients meeting the criteria for AUD diagnosis Company plans to submit ONWARD results to both European and U.S. regulatory agencies Conference call to be held today at 1:00 p.m. Eastern Time CHARLOTTESVILLE, Va., July 20, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-sta
CHARLOTTESVILLE, Va., July 18, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it plans to report topline results from the Company's ONWARD™ Phase 3 clinical trial on Wednesday, July 20, 2022. The Company plans to host a conference call at 1 PM Eastern Time on Wednesday (dial-in instructions to follow). About the ONWARD™ Trial The ONWARD Phase 3 clinical trial is a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, clinical study to evalu
CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, reminds investors that it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 856729. A webcast of the call may be accessed at h
CHARLOTTESVILLE, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments. The conference call may be accessed using the information provided on the Company's website at https://ir.adialpharma.com/ir-calendar. About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company
On track for trial completion in the first quarter of 2022 Adial to host business update call at 11AM Eastern today CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has reached its full enrollment target of 290 subjects in the Company's ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes. ONWARD tr
CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, will host a conference call at 11:00 A.M. Eastern Time today, August 20, 2021 to provide a clinical update and discuss the latest business developments. The conference call will be available via telephone by dialing toll free 844-369-8770 for U.S. callers or +1 862-298-0840 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2463/42538 or on the Company's webs
CHARLOTTESVILLE, Va., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it will host a conference call at 11:00 A.M. Eastern Time on Friday, August 20, 2021 to provide a clinical update and discuss the latest business developments. The conference call will be available via telephone by dialing toll free 844-369-8770 for U.S. callers or +1 862-298-0840 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2463/42538 o